Poriferous, LLC Secures Patent for DuraBloc™ Technology

Poriferous, LLC, a manufacturer of SuᐧPor® craniomaxillofacial and patient-specific implants, has received a patent for its DuraBloc™ technology from the U.S. Patent and Trademark Office (USPTO). The patent, U.S. Patent No. 12,653,677, was issued on June 16, 2026.

This new patent enhances the company's portfolio of proprietary technology, further establishing its reputation as an innovator in healthcare. The goal is to make premium-quality craniomaxillofacial implants more accessible and affordable.

SuᐧPor implants are made from biocompatible, porous polyethylene, allowing for tissue integration. The unique interconnecting pore structure promotes fibrovascular ingrowth, which helps ensure lasting results.

The DuraBloc™ technology features a smooth, nonporous underside while retaining the porous structure of the SuᐧPor implants. This design enables the incorporation of antibiotics into the implants during surgery to reduce infection risks while promoting fibrovascular integration. The dual-sided design of DuraBloc™ allows for easier removal of the implants without hindering tissue ingrowth.

Aaron Noble, CEO and Founder of Poriferous, stated, "We partner with surgeons to create and enhance our extensive catalogue of implants. Our newly patented DuraBloc™ technology addresses an ongoing need for implants that can be removed with greater ease. DuraBloc™ promotes tissue ingrowth for natural results without impeding the removal process."

Poriferous was founded to innovate surgical implants and provide high-quality results to patients. With years of research and collaboration with leading surgeons, the company aims to create implants that ensure seamless tissue integration and long-term stability.